A

lthough Sage Therapeutics’ (SAGE) experimental antidepressant has been great for its stock price — it soared 70 percent on Thursday after the company announced mostly positive results from a Phase 2 clinical trial of the compound it calls Sage-217, and kept climbing on Friday — the jury is very much out on whether it will ever be good for patients suffering from major depression.

“These are very interesting preliminary results but they’re certainly not definitive,” said S.J. Enna of the University of Kansas School of Medicine, an expert on brain neurotransmitter receptors such as those targeted by Sage’s compound. The 89 patients in the study “is a very small number, and if you pick a different patient group you may get different results.” Whether the 89 are representative of patients with moderate to severe depression will become clearer after the company runs a Phase 3 trial, he said.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy